<DOC>
	<DOCNO>NCT00045539</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , methotrexate thiotepa , work different way stop cancer cell divide stop grow die . Combining one drug may kill tumor cell . PURPOSE : Phase II trial study effectiveness combine methotrexate thiotepa treat patient newly-diagnosed primary CNS lymphoma .</brief_summary>
	<brief_title>Methotrexate Thiotepa Treating Patients With Newly Diagnosed Primary CNS Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : - Determine complete radiographic response patient newly diagnose primary CNS lymphoma treat methotrexate thiotepa . - Determine duration progression-free survival overall survival patient treat regimen . - Determine toxicity regimen patient . - Determine whether tumor expression BCL-6 associate response chemotherapy regimen survival patient . - Describe relationship initial response steroid ( administer ) , response chemotherapy regimen , survival patient . OUTLINE : This multicenter study . Patients receive thiotepa IV 15 minute day 1 . Patients also receive methotrexate IV 4 hour day 1 ( 8 hour thiotepa ) 14 . Beginning 24 hour start methotrexate infusion , patient receive leucovorin calcium IV orally every 6 hour rescue achieve . Treatment repeat every 28 day 4 course absence disease progression unacceptable toxicity . Patients achieve disappearance enhancement disease MRI receive additional 28-day course follow maintenance therapy comprise thiotepa methotrexate month 11 course . Patients undergo neuro-ophthalmologic exam annually 2 year . Patients follow every 2 month . PROJECTED ACCRUAL : A total 23-39 patient accrue study within 8-20 month .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Thiotepa</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm primary CNS lymphoma Confirmed 1 following : Brain biopsy resection CSF cytology Positive cytology immunohistochemical diagnosis monoclonality measurable intracranial tumor Vitreal biopsy Measurable contrastenhancing disease postoperative , pretreatment MRI CT scan No radiographic evidence ascites pleural effusion PATIENT CHARACTERISTICS : Age 18 Performance status Karnofsky 60100 % Life expectancy Not specify Hematopoietic Absolute neutrophil count least 1,500/mm^3 Platelet count least 100,000/mm^3 Hepatic Bilirubin great 2.0 mg/dL SGOT great 4 time upper limit normal Renal Creatinine great 2 mg/dL Creatinine clearance least 50 mL/min Other Mini mental score least 15 HIV negative Able achieve hydration No malignancy within past 5 year except curatively treat basal cell squamous cell skin cancer carcinoma situ No allergy methotrexate No serious infection No medical illness would preclude study participation Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy No prior immunotherapy biologic therapy disease Chemotherapy No prior chemotherapy disease No concurrent chemotherapeutic agent Endocrine therapy No prior hormonal therapy disease Prior glucocorticoid therapy allow Radiotherapy No prior radiotherapy disease No prior cranial irradiation Surgery See Disease Characteristics Other At least 1 week since prior salicylate , nonsteroidal antiinflammatory drug , probenecid , folic acid , sulfonamide medication No concurrent investigational agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2005</verification_date>
	<keyword>primary central nervous system non-Hodgkin lymphoma</keyword>
</DOC>